NexGel Inc (NXGL)
NASDAQ:NXGL
Want to see NXGL full AI Analyst Report?
NXGL Stock Chart & Stats
$1.64
-$0.06(-1.71%)
At close: 4:00 PM EST
$1.64
-$0.06(-1.71%)
Day’s Range― - ―
52-Week Range$0.48 - $2.89
Previous CloseN/A
Volume27.00K
Average Volume (3M)50.95K
Market Cap
$6.51M
Enterprise Value$9.46M
Total Cash (Recent Filing)$208.00K
Total Debt (Recent Filing)$4.29M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 18, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding9,225,242
10 Day Avg. Volume60,354
30 Day Avg. Volume50,949
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.84
Price to Sales (P/S)1.11
P/FCF Ratio-9.17
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue0.84
Enterprise Value/Gross Profit2.16
Enterprise Value/Ebitda-4.23
Forecast
1Y Price Target
$2.00Price Target Upside21.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.37
Revenue Forecast (FY)$24.06M
Bulls Say, Bears Say
Bulls Say
Pro Forma Scale From BioNX AcquisitionAcquiring BioNX meaningfully increases scale and diversifies revenue into higher‑margin regenerative biomaterials. Tripling pro forma revenue and expected immediate accretion materially improves the firm's ability to absorb fixed costs and accelerates a structural path toward sustainable profitability if integration proceeds as planned.
Strategic Financing And Sequence PartnershipSequence's capital, manufacturing role and board representation bolster execution capacity, distribution reach and governance. This strategic support reduces long‑term operational execution risk, improves access to manufacturing scale, and aligns an active investor with incentives to accelerate commercialization and product development.
Commercial Product Footprint And PipelineOwning commercially approved products placed in ~500 hospitals provides recurring, reimbursement‑backed revenue and a sales base to cross‑sell. A near‑term 510(k) device pipeline creates medium‑term organic growth opportunities, supporting durable revenue expansion beyond one‑off product sales if commercialization succeeds.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow forces dependence on external financing to fund operations and integration costs. Over the next 2–6 months, this structural cash shortfall raises execution risk, could constrain investment in sales/R&D, and makes the company vulnerable if additional financings are delayed or diluted.
Rising Leverage Reduces FlexibilityDebt roughly equal to equity increases interest and refinancing burdens for a small company still loss‑making. Higher leverage narrows strategic options, raises covenant and liquidity risk during integration, and could pressure margins if servicing costs or covenants force operational trade‑offs while profitability remains elusive.
Operating Losses And Weakening Revenue MomentumDespite improved gross margins, operating cost structure and legacy product underperformance have kept net losses persistent. Slowing top‑line momentum means the company must realize promised acquisition accretion and hospital sales to reverse losses; failure to do so would prolong dependence on dilutive financing and delay sustainable profitability.
NexGel Inc News
NXGL FAQ
What was NexGel Inc’s price range in the past 12 months?
NexGel Inc lowest stock price was $0.48 and its highest was $2.89 in the past 12 months.
What is NexGel Inc’s market cap?
NexGel Inc’s market cap is $6.51M.
When is NexGel Inc’s upcoming earnings report date?
NexGel Inc’s upcoming earnings report date is Aug 18, 2026 which is in 63 days.
How were NexGel Inc’s earnings last quarter?
Currently, no data Available
Is NexGel Inc overvalued?
According to Wall Street analysts NexGel Inc’s price is currently Undervalued.
Does NexGel Inc pay dividends?
NexGel Inc does not currently pay dividends.
What is NexGel Inc’s EPS estimate?
NexGel Inc’s EPS estimate is -0.12.
How many shares outstanding does NexGel Inc have?
NexGel Inc has 9,225,242 shares outstanding.
What happened to NexGel Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NexGel Inc?
Currently, no hedge funds are holding shares in NXGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NexGel Inc
NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations. The company was founded in 1997 and operated under the name AquaMed Technologies, Inc. until it rebranded as NEXGEL, Inc. in November 2019. Its headquarters are located in Langhorne, Pennsylvania.
NXGL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a transformational acquisition (BioNX), strategic financing and partnership with Sequence LifeScience, strengthened leadership, a commercial product portfolio in ~500 hospitals, and pro forma projections to triple revenue to ~$35M and be accretive — all significant positives. Offsetting these are near‑term operational and liquidity pressures: Q1 revenue declined ~5.7% YoY, cash on hand fell to $1.8M, SG&A is elevated, and some legacy consumer products and key customer relationships have underperformed. Management reported early signs of recovery and initial BioNX sales beginning in Q2, but timing and execution risk remain notable.View all NXGL earnings summariesNXGL Stock 12 Month Forecast
Average Price Target
$2.00
▲(21.95% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
Sanara MedTech
―
Femasys
―
Ownership Overview
12.84% Insiders
1.13% Mutual Funds
0.95% Other Institutional Investors
84.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---